Type 1 Diabetes – Global Drug Forecast and Market Analysis to 2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Type 1 Diabetes (T1D), is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Insulin is the hormone that is needed for the transport of glucose from blood into cells, and without it the body is driven into a hyperglycemic state. Left untreated, this leads to death. There is no cure for T1D, and it is managed as a chronic condition through injections of exogenous insulin. There are other types of diabetes such as Type 2 Diabetes (developed resistance to insulin), gestational diabetes, latent autoimmune diabetes in adults, and diabetes that occurs as a symptom of other diseases. This report focuses on T1D.
It is expected that 15 therapeutics will launch in the Type 1 Diabetes (T1D) market in the eight major markets (8MM*) before 2030. They include Adocia’s BioChaperone Insulin lispro, an ultra-fast prandial insulin; Zealand Pharma’s dasiglucagon, a liquid-stable glucagon to manage hypoglycemia for use in a bihormonal pump; and Provention Bio’s teplizumab, the first preventative therapeutic for T1D. Despite this robust pipeline, there are still considerably high unmet needs within the space, all of which relate to the lack of a disease-modifying therapeutic that combats the autoimmune-mediated attack of beta cells in T1D patients.
GlobalData’s recent report reveals that over the next 10 years, the T1D pipeline is set to deliver innovative therapies that aim to improve disease management. These include novel second-generation insulin analogs, adjunct therapies, and the first disease-modifying therapeutics for T1D.
Samisha Khangaonkar, Pharma Analyst at GlobalData, comments: “Therapeutics that focus on the preservation of the remaining beta cells are becoming more critical for the long-term management of T1D. T1D patients with residual beta cell function require smaller doses of insulin, which can improve side effects and compliance. While many of these disease-modifying therapeutics are far from a cure for T1D, their effects may still have a significant impact on the long-term prognosis for T1D patients.”
Advances in insulin therapies such as the development of insulin analogs, novel/targeted approaches to administration, continuous glucose monitoring (CGM), and novel pens and devices for administration have all contributed to the improved treatment of T1D patients. However, even with these advances, the majority of T1D patients do not achieve the glycemic targets set by national and international guidelines. As such, the overall quality of life of a T1D patient has not improved, and the life expectancy is still 10–15 years less than the healthy population.
Khangaonkar continues: “It is disappointing that hypoglycemia and weight gain are still risks associated with all insulin therapies, and the threat of hypoglycemia as a consequence of poor glycemic control poses a major barrier to optimizing glycemic control in T1D patients.
“The need for a treatment that lowers blood glucose to the target levels without causing hypoglycemic events or weight gain is still one of the largest unmet needs in T1D treatment. Increased compliance and targeted patient education are additional unmet needs that have significant impacts on patient care, and are aspects of treatment often overlooked by drug developers.”
*8MM (US, France, Germany, Italy, Spain, UK, Japan, and Canada)
Scope
- Overview of T1D including epidemiology, disease etiology and management.
- Topline T1D drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
KEY QUESTIONS ANSWERED
Despite the existence of numerous well-established treatment options in the T1D space, a few-yet significant-unmet needs remain.
– Which unmet needs are the most pressing in the 8MM?
– Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
Novel insulins continue to be developed, and the first disease-modifying therapeutics may emerge over the forecast period.
– What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
– What do KOLs say about their clinical and commercial positioning?
The T1D market has been dominated by three main companies since the discovery of insulin 100 years ago, though more recently new players have started to emerge.
– Which have been historically the companies leading the way?
– What new companies are emerging in the space?
Key Highlights
The diagnosed prevalence of T1D is expected to increase over the 10-year forecast period due changing population demographics, and an increased understanding of risk factors and environmental factors that may trigger the onset of T1D.
The potential launch of 5 disease-modifying therapeutics will increase the number of patients who, at diagnosis, can prolong their endogenous insulin secretion to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that find success in the market. The drive toward closed-loops systems, like an artificial pancreas, places a great need for ultra-fast insulins to launch in the market, and prompts more collaboration between across the industry.
Despite the variety of insulins currently available to T1D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global T1D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T1D market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T1D therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Eli Lilly
Sanofi
Biocon/Viatris
Mannkind Corporation
J&J
Diasome
Adocia
Diamyd Medical
Zealand Pharma
AstraZeneca
Lexicon Therapeutics
vTv Therapeutics
Provention Bio
Dompe Farmaceuti
PolTreg
CellTrans
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.